Incorporated in August 2004, Corona Remedies Limited operates as a pharmaceutical company with activities in the development, manufacturing, and marketing of branded formulations. The company’s product portfolio covers multiple therapeutic segments, including women’s healthcare, cardio-diabeto, pain management, urology, and other multispecialty areas. As of June 30, 2025, the portfolio consisted of 71 brands across these categories, including products in vitamins and minerals, nutrition, gastrointestinal, and respiratory segments. The company engages with healthcare professionals through a marketing and distribution network present across 22 states, supported by 2,671 medical representatives. This network is positioned to facilitate product availability in different regions of the Indian pharmaceutical market.
Corona Remedies Limited operates two manufacturing facilities located in Gujarat, with a reported aggregate installed formulation capacity of 1,285.44 million units per annum. Based on available domestic sales data for MAT June 2025, the women’s healthcare segment accounted for 28.56% of sales at ₹4,080.26 million, cardio-diabeto products accounted for 23.38% at ₹3,339.96 million, pain management contributed 11.79% at ₹1,684.38 million, and the urology segment accounted for 4.53% at ₹646.65 million. These figures reflect the contribution of individual therapeutic segments within the company’s product basket. The information provided reflects publicly available disclosures and can be cross-checked with official filings for accuracy.